Showing 941-950 of 1635 results for "".
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- Nacuity Pharmaceuticals Achieves Target Enrollment for Phase 1/2 Clinical Trial of NPI-001 for the Treatment of RP Associated with Usher Syndromehttps://modernod.com/news/nacuity-pharmaceuticals-achieves-target-enrollment-for-phase-12-clinical-trial-of-npi-001-for-the-treatment-of-rp-associated-with-usher-syndrome/2481641/Nacuity Pharmaceuticals announced that target enrollment of 48 patients has been reached in the SLO-RP phase 1/2 clinical trial of NPI-001 tablets in patients with retinitis pigmentosa (RP) associated with Usher syndrome (USH). “We are pleased to reach our target enrollment,
- Nanoscope Therapeutics Presents Key Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of RP at ARVOhttps://modernod.com/news/nanoscope-therapeutics-presents-key-results-from-phase-2b-restore-trial-of-mco-010-for-the-treatment-of-rp-at-arvo/2481583/Nanoscope Therapeutics announced the presentation of key data from its phase 2b multicenter, randomized, double-masked, sham-controlled RESTORE clinical trial (NCT04945772) of MCO-010 at the ARV
- Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b Trial of Optogenetic Therapy for RPhttps://modernod.com/news/nanoscope-therapeutics-announces-positive-topline-results-from-phase-2b-trial-of-optogenetic-therapy-for-rp/2481504/Nanoscope Therapeutics announced topline results from the phase 2b RESTORE clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy for vision restoration in advanced retinitis pigmentosa (RP), irrespective of gene mutation. MCO-0
- Staar Surgical Names Warren Foust Chief Operating Officer; Magda Michna, PhD, Chief Clinical, Regulatory and Medical Affairs Officerhttps://modernod.com/news/staar-surgical-names-warren-foust-chief-operating-officer-magda-michna-phd-chief-clinical-regulatory-and-medical-affairs-officer/2481498/Staar Surgical announced that Warren Foust has been named Chief Operating Officer, and Magda Michna, PhD, has been named Chief Clinical, Regulatory and Medical Affairs Officer. Both positions will report to Staar Surgical’s President and CEO, Tom Frinzi. “The addition of two
- Graybug Announces Name and Trading Symbol Changehttps://modernod.com/news/graybug-announces-name-and-trading-symbol-change/2481478/Graybug Vision announced that it has changed its name to CalciMedica Inc., effective today. In connection with the name change, the company has changed its trading symbol to “CALC.” The company’s common stock will commence trading on March 21, 2023 on the Nasdaq Global
- Oculis Announces US Public Listing on Nasdaqhttps://modernod.com/news/oculis-announces-us-public-listing-on-nasdaq/2481444/Starting today, Oculis’ shares will trade on the Nasdaq Stock Market under the ticker symbol "OCS." The listing comes after successfully closing the business combination between European Biotech Acquisition Corp. (EBAC) and Oculis SA. The business combination was un
- VSP Vision Names New President of VSP Ventureshttps://modernod.com/news/kathleen-steele-named-president-of-vsp-ventures/2481370/VSP Vision announced that Kathleen Steele has been named president of VSP Ventures. In the role, Ms. Steele will lead the company’s business unit that provides care-focused choices for doctors of optometry looking for practice transition options. She will report to Kate Renwick-Es
- Nanotechnology May Improve Gene Therapy for Blindnesshttps://modernod.com/news/nanotechnology-may-improve-gene-therapy-for-blindness/2481350/Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness, according to the National Eye Institute. A collaborative team of researchers with Oregon Health & Science University and Oreg
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care-1/2481275/Nanodropper has launched its 2022 Give the Gift of Vision program, an effort to donate 1,000 Nanodropper Adaptors to at-need patients in the United States and its global nonprofit partners, aiming to deliver better access to vision-saving care in low resource settings in Africa, Haiti, and e